Sotagliflozin + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Nephropathies
Conditions
Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Trial Timeline
Oct 31, 2024 → May 1, 2029
NCT ID
NCT06217302About Sotagliflozin + Placebo
Sotagliflozin + Placebo is a phase 3 stage product being developed by Dexcom for Diabetic Nephropathies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06217302. Target conditions include Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06217302 | Phase 3 | Recruiting |
Competing Products
20 competing products in Diabetic Nephropathies